You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydrocodeine
Accession NumberDB01551
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionDihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. [Wikipedia]
Structure
Thumb
Synonyms
DHC
Remedacen
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CodidolNot Available
ContugesicNot Available
DehaceNot Available
DF-118 ForteNot Available
DicogesicNot Available
HydrocodinNot Available
RemedacenNot Available
Brand mixtures
NameLabellerIngredients
Acetaminophen, Caffeine, Dihydrocodeine BitartrateXspire Pharma Llc
Aspirin, Caffeine, and Dihydrocodeine BitartrateCaraco Pharmaceutical Laboratories, Ltd
Centussin DhcCenturion Labs, Llc
Dihydrocodeine Bitartrate, Acetaminophen and CaffeinePhysicians Total Care, Inc.
J-cof DhcJay Mac Pharmaceuticals
J-max DhcJay Mac Pharmaceuticals
Poly Hist DhcPoly Pharmaceuticals, Inc.
Poly-tussin EXPoly Pharmaceuticals, Inc.
SynalgosCaraco Pharma Inc.
TrezixWra Ser Llc
Salts
Name/CASStructureProperties
Dihydrocodeine bitartrate
Thumb
  • InChI Key: ZGSZBVAEVPSPFM-HYTSPMEMSA-N
  • Monoisotopic Mass: 451.184231531
  • Average Mass: 451.467
DBSALT000048
Dihydrocodeine hydrobromide
ThumbNot applicableDBSALT000049
Dihydrocodeine hydrochloride
36418-29-8
Thumb
  • InChI Key: VMZXMTVGOAQUEN-FFHNEAJVSA-N
  • Monoisotopic Mass: 337.144471346
  • Average Mass: 337.841
DBSALT000050
Dihydrocodeine hydroiodide
5965-15-1
Thumb
  • InChI Key: QXBJOHDQNJOLNA-PKHFJCIDNA-N
  • Monoisotopic Mass: 429.080087059
  • Average Mass: 429.2925
DBSALT000051
Dihydrocodeine methyliodide
ThumbNot applicableDBSALT000052
Dihydrocodeine phosphate
Thumb
  • InChI Key: HFBYLYCMISIEMM-FFHNEAJVSA-N
  • Monoisotopic Mass: 399.144688703
  • Average Mass: 399.3753
DBSALT000053
Dihydrocodeine sulfate
ThumbNot applicableDBSALT000054
Dihydrocodeine tartrate
ThumbNot applicableDBSALT000055
Categories
UNIIN9I9HDB855
CAS number125-28-0
WeightAverage: 301.3801
Monoisotopic: 301.167793607
Chemical FormulaC18H23NO3
InChI KeyInChIKey=RBOXVHNMENFORY-DNJOTXNNSA-N
InChI
InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-ol
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationDihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]
PharmacodynamicsPossible opioid related side effects include, but are not limited to, drowsiness, nausea, headache, dry mouth, constipation, difficulty passing urine, and mild euphoria.
Mechanism of actionDihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. [3]
Related Articles
AbsorptionBioavailability is low (approximately 20%) if administered orally. This may be due to poor gastrointestinal absorption. It is also likely due to pre-systemic metabolism by the liver and intestinal wall. [2] The AUCs after oral and intravenous administration are similar (3203ug/l/h and 3401ug/l/h, respectively). [2] Time to peak values are 1.6 and 1.8hours for a 30mg and 60mg dose, respectively. The concentrations achieved were 71.8 ug/1 and 146 ug/1, respectively. [2]
Volume of distribution

The disposition of dihydrocodeine is described as a two compartment model. 2

Protein bindingNot Available
Metabolism

Metabolized in the liver by CYP 2D6 into an active metabolite, dihydromorphine, and by CYP 3A4 into secondary primary metabolite, nordihydrocodeine. A third primary metabolite is dihydrocodeine-6-glucuronide. [1] The time for mean peak concentration in acid metabolites is 1.76h and 1.98h for a 30 and 60mg dose, respectively. The concentrations achieved were 563 ug/1 and 1476 ug/1, respectively. [2]

Route of eliminationRenal elimination and urinary excretion. [1]
Half life4h
Clearance

Plasma clearance is approximately 300ml/min. 2

The pharmacokinetics of dihydrocodeine and active metabolite dihydromorphine have been reported to be linear. 1

The decline in plasma dihydrocodeine concentrations after intravenous administration has been described as bi-exponential, with a sleep decline in the initial 2h following administration, followed by a mono-exponential decline thereafter. Clearance was not dose dependent. 2

ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9974
Caco-2 permeable+0.8388
P-glycoprotein substrateSubstrate0.8754
P-glycoprotein inhibitor IInhibitor0.5937
P-glycoprotein inhibitor IINon-inhibitor0.9652
Renal organic cation transporterInhibitor0.5676
CYP450 2C9 substrateNon-substrate0.831
CYP450 2D6 substrateSubstrate0.9143
CYP450 3A4 substrateSubstrate0.7941
CYP450 1A2 substrateNon-inhibitor0.8554
CYP450 2C9 inhibitorNon-inhibitor0.9074
CYP450 2D6 inhibitorInhibitor0.7395
CYP450 2C19 inhibitorNon-inhibitor0.7689
CYP450 3A4 inhibitorNon-inhibitor0.8114
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.957
Ames testNon AMES toxic0.8074
CarcinogenicityNon-carcinogens0.9522
BiodegradationNot ready biodegradable0.9857
Rat acute toxicity2.9382 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9058
hERG inhibition (predictor II)Non-inhibitor0.8246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Liquidoral
Tabletoral
Syruporal
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point112.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.38 mg/mLALOGPS
logP1.58ALOGPS
logP1.55ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)14.15ChemAxon
pKa (Strongest Basic)9.33ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity83.64 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Igor Likhotvorik, “Preparation of dihydrocodeine from codeine.” U.S. Patent US06887999, issued May 03, 2005.

US06887999
General References
  1. Ammon S, Hofmann U, Griese EU, Gugeler N, Mikus G: Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22. [PubMed:10510141 ]
  2. Rowell FJ, Seymour RA, Rawlins MD: Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol. 1983;25(3):419-24. [PubMed:6628531 ]
  3. Schmidt H, Vormfelde SV, Walchner-Bonjean M, Klinder K, Freudenthaler S, Gleiter CH, Gundert-Remy U, Skopp G, Aderjan R, Fuhr U: The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106. [PubMed:12665158 ]
External Links
ATC CodesN02AA58N02AA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydrocodeine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydrocodeine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Dihydrocodeine can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Dihydrocodeine.
AcepromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydrocodeine.
adipiplonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydrocodeine.
AlimemazineAlimemazine may increase the hypotensive activities of Dihydrocodeine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydrocodeine.
AlvimopanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amiloride.
AmiodaroneThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydrocodeine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydrocodeine.
AmoxapineDihydrocodeine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydrocodeine.
AmperozideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Dihydrocodeine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydrocodeine.
AprepitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.
ArtemetherThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Asenapine.
AtazanavirThe metabolism of Dihydrocodeine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydrocodeine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydrocodeine.
AzaperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azaperone.
AzelastineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dihydrocodeine.
AzosemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydrocodeine.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydrocodeine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydrocodeine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydrocodeine.
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydrocodeine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benzyl alcohol.
BetaxololThe metabolism of Dihydrocodeine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydrocodeine.
BoceprevirThe metabolism of Dihydrocodeine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Dihydrocodeine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
BrimonidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydrocodeine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Dihydrocodeine.
BuprenorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Buprenorphine.
BupropionThe metabolism of Dihydrocodeine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydrocodeine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine.
ButacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydrocodeine.
ButorphanolButorphanol may decrease the analgesic activities of Dihydrocodeine.
ButorphanolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydrocodeine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dihydrocodeine.
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carisoprodol.
CelecoxibThe metabolism of Dihydrocodeine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydrocodeine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydrocodeine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydrocodeine.
ChloroquineThe metabolism of Dihydrocodeine can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydrocodeine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydrocodeine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Dihydrocodeine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydrocodeine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Dihydrocodeine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Dihydrocodeine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Dihydrocodeine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydrocodeine.
CitalopramDihydrocodeine may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Dihydrocodeine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Dihydrocodeine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Dihydrocodeine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clidinium.
ClobazamThe metabolism of Dihydrocodeine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with clomethiazole.
ClomipramineDihydrocodeine may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Dihydrocodeine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydrocodeine.
ClotrimazoleThe metabolism of Dihydrocodeine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Dihydrocodeine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clozapine.
CobicistatThe serum concentration of Dihydrocodeine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydrocodeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydrocodeine.
ConivaptanThe serum concentration of Dihydrocodeine can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Conivaptan.
CrizotinibThe metabolism of Dihydrocodeine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydrocodeine.
CyclosporineThe metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyproheptadine.
DabrafenibThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydrocodeine.
DapoxetineDihydrocodeine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydrocodeine.
DarunavirThe serum concentration of Dihydrocodeine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Dihydrocodeine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Dihydrocodeine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydrocodeine.
DesipramineThe metabolism of Dihydrocodeine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydrocodeine.
DesmopressinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Detomidine.
DexamethasoneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydrocodeine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydrocodeine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydrocodeine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydrocodeine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydrocodeine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydrocodeine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydrocodeine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.
DifenoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Difenoxin.
DihydroergotamineThe metabolism of Dihydrocodeine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydrocodeine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine.
DiltiazemThe metabolism of Dihydrocodeine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Dihydrocodeine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydrocodeine.
DoramectinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxepin.
DoxycyclineThe metabolism of Dihydrocodeine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
DoxylamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
DronedaroneThe metabolism of Dihydrocodeine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dihydrocodeine.
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dihydrocodeine.
DuloxetineThe metabolism of Dihydrocodeine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydrocodeine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dihydrocodeine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Dihydrocodeine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efonidipine.
EliglustatThe metabolism of Dihydrocodeine can be decreased when combined with Eliglustat.
EluxadolineDihydrocodeine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydrocodeine.
EntacaponeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Entacapone.
EnzalutamideThe serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eplerenone.
ErythromycinThe metabolism of Dihydrocodeine can be decreased when combined with Erythromycin.
EscitalopramDihydrocodeine may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Dihydrocodeine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydrocodeine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydrocodeine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.
EthanolDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dihydrocodeine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydrocodeine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydrocodeine.
EthosuximideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dihydrocodeine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydrocodeine.
EtidocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydrocodeine.
EtoperidoneDihydrocodeine may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydrocodeine.
EtravirineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydrocodeine.
FenfluramineDihydrocodeine may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrocodeine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.
FexofenadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flibanserin.
FluconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydrocodeine.
FluoxetineDihydrocodeine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydrocodeine.
FluphenazineFluphenazine may increase the hypotensive activities of Dihydrocodeine.
FluphenazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydrocodeine.
FluspirileneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluticasone Propionate.
FluvoxamineDihydrocodeine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Dihydrocodeine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Dihydrocodeine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.
Fusidic AcidThe serum concentration of Dihydrocodeine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrocodeine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydrocodeine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydrocodeine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydrocodeine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydrocodeine.
GuanfacineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydrocodeine.
HaloperidolThe metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydrocodeine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dihydrocodeine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydrocodeine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydrocodeine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydrocodeine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dihydrocodeine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dihydrocodeine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
HydroxyzineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydrocodeine.
IdelalisibThe serum concentration of Dihydrocodeine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iloperidone.
ImatinibThe metabolism of Dihydrocodeine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Dihydrocodeine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Imipramine.
IndalpineDihydrocodeine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.
IndinavirThe metabolism of Dihydrocodeine can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.
IsavuconazoniumThe metabolism of Dihydrocodeine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydrocodeine.
IsoniazidThe metabolism of Dihydrocodeine can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Isosorbide.
IsradipineThe metabolism of Dihydrocodeine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Dihydrocodeine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrocodeine.
KetazolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketobemidone.
KetoconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydrocodeine.
LevocabastineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydrocodeine.
LevomilnacipranDihydrocodeine may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydrocodeine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydrocodeine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydrocodeine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydrocodeine.
LofentanilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lofentanil.
LopinavirThe metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydrocodeine.
LorcaserinThe metabolism of Dihydrocodeine can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Dihydrocodeine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydrocodeine.
Lu AA21004Dihydrocodeine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dihydrocodeine.
LuliconazoleThe serum concentration of Dihydrocodeine can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Dihydrocodeine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.
MeclizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydrocodeine.
MelperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Dihydrocodeine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydrocodeine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.
MersalylThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Dihydrocodeine.
MesoridazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.
MethadoneThe metabolism of Dihydrocodeine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydrocodeine.
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydrocodeine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydrocodeine.
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydrocodeine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Dihydrocodeine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydrocodeine.
MethsuximideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Dihydrocodeine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydrocodeine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydrocodeine.
MetolazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.
MetoprololThe metabolism of Dihydrocodeine can be decreased when combined with Metoprolol.
MetyrosineDihydrocodeine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.
MifepristoneThe metabolism of Dihydrocodeine can be decreased when combined with Mifepristone.
MilnacipranDihydrocodeine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
MirabegronThe metabolism of Dihydrocodeine can be decreased when combined with Mirabegron.
MirtazapineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dihydrocodeine.
MitotaneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Dihydrocodeine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Dihydrocodeine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dihydrocodeine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
NabiloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nabilone.
NafcillinThe serum concentration of Dihydrocodeine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Dihydrocodeine.
NalbuphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Dihydrocodeine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Dihydrocodeine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Dihydrocodeine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Dihydrocodeine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dihydrocodeine.
OlanzapineDihydrocodeine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine.
OlaparibThe metabolism of Dihydrocodeine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydrocodeine.
OpiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Opium.
OrphenadrineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dihydrocodeine.
OsanetantThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant.
OsimertinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydrocodeine.
OxprenololThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydrocodeine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrocodeine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrocodeine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydrocodeine.
PalbociclibThe serum concentration of Dihydrocodeine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydrocodeine.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydrocodeine.
PanobinostatThe metabolism of Dihydrocodeine can be decreased when combined with Panobinostat.
ParaldehydeDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dihydrocodeine.
ParoxetineDihydrocodeine may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.
PentazocinePentazocine may decrease the analgesic activities of Dihydrocodeine.
PentazocineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydrocodeine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydrocodeine.
PerampanelThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Dihydrocodeine.
PerphenazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydrocodeine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydrocodeine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Dihydrocodeine.
PhenytoinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydrocodeine.
PipamperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.
PipotiazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.
PiretanideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.
PosaconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.
PramipexoleDihydrocodeine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydrocodeine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydrocodeine.
PrimidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydrocodeine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Dihydrocodeine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydrocodeine.
PromazinePromazine may increase the hypotensive activities of Dihydrocodeine.
PromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Dihydrocodeine.
PromethazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydrocodeine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydrocodeine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quinethazone.
QuinidineQuinidine may decrease the analgesic activities of Dihydrocodeine.
QuinineThe metabolism of Dihydrocodeine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ramelteon.
RamosetronDihydrocodeine may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Dihydrocodeine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydrocodeine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydrocodeine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydrocodeine.
RifabutinThe metabolism of Dihydrocodeine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Dihydrocodeine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Dihydrocodeine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.
RitonavirThe metabolism of Dihydrocodeine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Dihydrocodeine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Romifidine.
RopiniroleDihydrocodeine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Dihydrocodeine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydrocodeine.
RotigotineDihydrocodeine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydrocodeine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Dihydrocodeine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrocodeine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydrocodeine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine.
SertindoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sertindole.
SertralineDihydrocodeine may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Dihydrocodeine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydrocodeine.
SildenafilThe metabolism of Dihydrocodeine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Dihydrocodeine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Dihydrocodeine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydrocodeine.
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spironolactone.
St. John's WortThe serum concentration of Dihydrocodeine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydrocodeine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.
SulfisoxazoleThe metabolism of Dihydrocodeine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydrocodeine.
SuvorexantThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tasimelteon.
TelaprevirThe metabolism of Dihydrocodeine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Dihydrocodeine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydrocodeine.
TerbinafineThe metabolism of Dihydrocodeine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrodotoxin.
ThalidomideDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dihydrocodeine.
TheobromineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydrocodeine.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydrocodeine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydrocodeine.
ThioridazineThioridazine may increase the hypotensive activities of Dihydrocodeine.
ThioridazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiagabine.
TiclopidineThe metabolism of Dihydrocodeine can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydrocodeine.
TipranavirThe metabolism of Dihydrocodeine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.
TocilizumabThe serum concentration of Dihydrocodeine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydrocodeine.
TolvaptanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrocodeine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Dihydrocodeine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tranylcypromine.
TrazodoneDihydrocodeine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydrocodeine.
TriamtereneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydrocodeine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Dihydrocodeine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Dihydrocodeine.
TriflupromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydrocodeine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydrocodeine.
TrimipramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydrocodeine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydrocodeine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydrocodeine.
UlaritideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydrocodeine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydrocodeine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.
VenlafaxineThe metabolism of Dihydrocodeine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vigabatrin.
VilazodoneDihydrocodeine may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Voriconazole.
VortioxetineDihydrocodeine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dihydrocodeine.
XylazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydrocodeine.
ZiconotideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziconotide.
ZimelidineDihydrocodeine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dihydrocodeine.
ZonisamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydrocodeine.
ZotepineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.
Food Interactions
  • Alcohol may enhance CNS depressant effects

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23